https://allsci.com/news/clinical-trials/ivonescimab-nsclc-trial-cuts-death-risk-27-versus/ AllScien 2026-09-14T09:19:17.648373Z Ivonescimab cuts death risk 27% versus Keytruda in Phase III NSCLC trial https://allsci.com/news/clinical-trials/tam-peli-sclc-trial-medilinks-cuts-death-risk-54/ AllScien 2026-09-14T09:09:22.481799Z Roche-partnered Tam-Peli cuts death risk 54% in Phase III SCLC trial